MENS
HEALTHCAREJyong Biotech Ltd
$2.15+0.08 (+3.86%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MENS Today?
No stock-specific AI insight has been generated for MENS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.43$67.00
$2.15
Fundamentals
Market Cap$156M
P/E Ratio—
EPS$-0.04
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume39K
Avg Volume (10D)—
Shares Outstanding74.2M
MENS News
17 articles- Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug PortfolioYahoo Finance·Apr 29, 2026
- Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2Yahoo Finance·Mar 28, 2026
- Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into AsiaYahoo Finance·Feb 13, 2026
- CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent dropYahoo Finance·Feb 10, 2026
- Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic ValueYahoo Finance·Jan 30, 2026
- Jyong Biotech Responds to Share Price and Volume MovementYahoo Finance·Dec 19, 2025
- Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market EntryYahoo Finance·Dec 4, 2025
- Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS DrugsYahoo Finance·Nov 24, 2025
- Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8Yahoo Finance·Nov 21, 2025
- Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price VolatilityYahoo Finance·Nov 21, 2025
- Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive OutcomesYahoo Finance·Nov 20, 2025
- Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech AwardsYahoo Finance·Sep 29, 2025
- Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in TaipeiYahoo Finance·Sep 18, 2025
- Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer PreventionYahoo Finance·Sep 16, 2025
- Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current ValuationYahoo Finance·Sep 14, 2025
- Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)Yahoo Finance·Aug 22, 2025
- Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International ConventionYahoo Finance·Jul 22, 2025
All 17 articles loaded
Price Data
Open$0.00
Previous Close$2.07
Day High$0.00
Day Low$0.00
52 Week High$67.00
52 Week Low$1.43
52-Week Range
$1.43$67.00
$2.15
Fundamentals
Market Cap$156M
P/E Ratio—
EPS$-0.04
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume39K
Avg Volume (10D)—
Shares Outstanding74.2M
About Jyong Biotech Ltd
Jyong Biotech Ltd. (ticker: MENS) is a forward-thinking biotechnology company dedicated to advancing therapeutic solutions for cancer and autoimmune diseases. Utilizing its expertise in genomics and molecular biology, the company has developed a robust pipeline of innovative treatments backed by a strong intellectual property portfolio. With strategic collaborations in the biopharmaceutical sector, Jyong Biotech aims to leverage emerging market opportunities while maintaining a focus on scientific rigor and patient-centered care, positioning itself as a significant contributor to the future of healthcare innovation.
Listed June 17, 2025
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—